Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
Autor: | Dammer EB; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA., Ping L; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA., Duong DM; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA., Modeste ES; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA., Seyfried NT; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, USA.; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA., Lah JJ; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA., Levey AI; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA.; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA., Johnson ECB; Goizueta Alzheimer's Disease Research Center, Emory University School of Medicine, Whitehead Building-Suite 505C, 615 Michael Street, Atlanta, GA, 30322, USA. erik.c.b.johnson@emory.edu.; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. erik.c.b.johnson@emory.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Alzheimer's research & therapy [Alzheimers Res Ther] 2022 Nov 17; Vol. 14 (1), pp. 174. Date of Electronic Publication: 2022 Nov 17. |
DOI: | 10.1186/s13195-022-01113-5 |
Abstrakt: | Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer's disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer's disease cerebrospinal fluid (CSF) and plasma from the same subjects (n=18 control, n=18 AD) using three different proteomic platforms-SomaLogic SomaScan, Olink proximity extension assay, and tandem mass tag-based mass spectrometry-to assess which protein markers in these two biofluids may serve as reliable biomarkers of AD pathophysiology observed from unbiased brain proteomics studies. Median correlation of overlapping protein measurements across platforms in CSF (r~0.7) and plasma (r~0.6) was good, with more variability in plasma. The SomaScan technology provided the most measurements in plasma. Surprisingly, many proteins altered in AD CSF were found to be altered in the opposite direction in plasma, including important members of AD brain co-expression modules. An exception was SMOC1, a key member of the brain matrisome module associated with amyloid-β deposition in AD, which was found to be elevated in both CSF and plasma. Protein co-expression analysis on greater than 7000 protein measurements in CSF and 9500 protein measurements in plasma across all proteomic platforms revealed strong changes in modules related to autophagy, ubiquitination, and sugar metabolism in CSF, and endocytosis and the matrisome in plasma. Cross-platform and cross-biofluid proteomics represents a promising approach for AD biomarker development. (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |